deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03104842

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients

Sponsor: Universitätsklinikum Hamburg-Eppendorf

Conditions Multiple Myeloma
Interventions Carfilzomib Dexamethasone Isatuximab Lenalidomide
Updated 14 times since 2017 Last updated: May 26, 2024 Started: Aug 15, 2017 Primary completion: May 31, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Myeloma, this trial is ongoing. The trial is conducted by Universitätsklinikum Hamburg-Eppendorf and has accumulated 14 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2017 – ~Nov 2017 · 6 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Aug 2019 · 12 months · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Feb 2023 · 7 months · monthly snapshot~Feb 2023 – ~Jun 2024 · 16 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 9 earlier versions

  1. Jul 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  2. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  3. Mar 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  5. Aug 2019 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Aug 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  8. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. May 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Universitätsklinikum Hamburg-Eppendorf
Data source: Universitätsklinikum Hamburg-Eppendorf

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bielefeld, Germany , Bonn, Germany , Chemnitz, Germany , Cologne, Germany , Eschweiler, Germany , Essen, Germany , Hamburg, Germany , Heidelberg, Germany , Mainz, Germany and 4 more locations